Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorKetenci, Sema
dc.contributor.authorAynacıoğlu, Ahmet Şükrü
dc.date.accessioned2022-11-01T07:26:36Z
dc.date.available2022-11-01T07:26:36Z
dc.date.issued2021en_US
dc.identifier.citationKetenci, Sema., Aynacioglu, Ahmet Şükrü., (03.10.2021). The growth factor/cytokine midkine may participate in cytokine storm and contribute to the pathogenesis of severe acute respiratory syndrome coronavirus 2-infected patients. The Egyptian Journal of Bronchology (2021). 15(1). pp.1-6. https://doi.org/10.1186/s43168-021-00087-6 ‌en_US
dc.identifier.issn1687-8426
dc.identifier.issn2314-8551
dc.identifier.uri10.1186/s43168-021-00087-6
dc.identifier.urihttps://hdl.handle.net/20.500.12900/86
dc.description.abstractBackground The current coronavirus disease 2019 (COVID-19) outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged in Wuhan, China, and has rapidly become a global challenge, creating major challenges to health systems in almost every country in the world it has turned into a pandemic. COVID-19 poses a risky clinical situation that can range from mild illness to severe respiratory failure, requiring admission to intensive care. Main body It is known that SARS-CoV-2 infection causes a cytokine storm in some critically ill patients. However, more and more evidence showed that there is a dramatic increase in cytokine levels in patients diagnosed with COVID-19. Midkine (MK) is involved in various physiological and pathological processes, which some of them are desired and beneficial such as controlling tissue repair and antimicrobial effects, but some others are harmful such as promoting inflammation, carcinogenesis, and chemoresistance. Also, MK is expressed in inflammatory cells and released by endothelial cells under hypoxic conditions. Conclusions Considering all this information, there are strong data that midkine, an important cytokine known to increase in inflammatory diseases, may be overexpressed in patients who are positive for COVID-19. The overexpression of MK reveals a picture leading to fibrosis and damage in the lung. Therefore, questions arise about how the expression of MK changes in COVID-19 patients and can we use it as an inflammation biomarker or in the treatment protocol in the future.en_US
dc.language.isoengen_US
dc.publisherThe Egyptian Journal of Bronchologyen_US
dc.relation.isversionof10.1186/s43168-021-00087-6en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMidkineen_US
dc.subjectCOVID-19en_US
dc.subjectSARS-CoV-2en_US
dc.subjectCytokineen_US
dc.subjectStorm Inflammationen_US
dc.titleThe Growth Factor/cytokine Midkine May Participate in Cytokine Storm and Contribute to the Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus 2-infected Patienten_US
dc.typearticleen_US
dc.departmentİstanbul Atlas Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.authoridSema Ketenci / 0000-0002-6695-7003en_US
dc.authoridAhmet Şükrü Aynacıoğlu / 0000-0001-5393-4606en_US
dc.contributor.institutionauthorKetenci, Sema
dc.contributor.institutionauthorAynacıoğlu, Ahmet Şükrü
dc.identifier.volume15en_US
dc.identifier.issue1en_US
dc.identifier.startpage1en_US
dc.identifier.endpage6en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster